TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11511559
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (lansoprazole and tranexamic acid)
Study: 9255202
Drug: Aerosolized recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized recombinant human deoxyribonuclease (rhDNase) 10 mg twice a day for 14 days, followed by a 14-day washout period for a total of 6 treatment cycles.
Study: 29558034
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of modified Sinaki exercises and Nordic walking
Study: 23388687
Drug: 0.1% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tacrolimus ointment once a week
Study: 23388687
Drug: 0.1% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tacrolimus ointment twice a week
Study: 23388687
Drug: Vehicle twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle twice a week
Study: 17142206
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (OM) 0.4 mg/kg mixed with cherry juice
Study: 17142206
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (INM) 0.2 mg/kg as drops
Study: 17142206
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral cherry juice or intranasal serum physiologic)
Study: 14610441
Drug: Individualized daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized daily schedule
Study: 10910832
Drug: Remifentanil combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil combined with intrathecal morphine (R group)
Study: 8929583
Drug: Cr (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr (0.5 g x kg‐1 x day‐1)
Study: 8929583
Drug: Cr (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr (0.5 g x kg‐1 x day‐1) + C (5 mg x kg‐1 x day‐1)
Study: 1533376
Drug: Danazol 400
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 400 mg/d orally
Study: 25851776
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate loading (CHL) drinks consumed 12 and 2 hours presurgery, and immediate postoperative peripheral parenteral nutrition.
Study: 20926754
Drug: BG9928 (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG9928 (0.03 mg/kg)
Study: 20926754
Drug: BG9928 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG9928 (0.3 mg/kg)
Study: 20926754
Drug: BG9928 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG9928 (1.0 mg/kg)
Study: 20926754
Drug: BG9928 (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG9928 (3.0 mg/kg)
Study: 16954936
Drug: High-concentration contrast
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration contrast medium (370 mg I/mL)
Study: 16954936
Drug: Low-concentration contrast
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration contrast medium (300 mg I/mL)
Study: 15250771
Drug: Multiple treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple treatments with indocyanine green (ICG) and near infrared (NIR) diode laser phototherapy
Study: 15250771
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment with indocyanine green (ICG) and near infrared (NIR) diode laser phototherapy
Study: 9171066
Drug: Low-dose m-BACOD
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose m-BACOD with GM-CSF (n=98)
Study: 9171066
Drug: Standard-dose m-BACOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose m-BACOD with GM-CSF (n=94)
Study: 24075427
Drug: Enoxaparin in
Normalized name: enoxaparin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin in balanced salt solution (BSS)
Study: 16424718
Drug: Alanyl-glutamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanyl-glutamine (0.4 g x kg body weight(-1) x 24 hrs(-1))
Study: 12829670
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose radiotherapy (50.4 Gy in 28 fractions)
Study: 12829670
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose radiotherapy (64.8 Gy in 36 fractions)
Study: 12829670
Drug: Radiotherapy (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (both doses)
Study: 9607553
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal treatment (NHT) with leuprolide plus cyproterone acetate
Study: 319424
Drug: Indomethacin +
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin + aspirin (150 mg indomethacin daily, 1500 mg aspirin daily)
Study: 15955382
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg/day)
Study: 31339011
Drug: Glimepiride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (2 mg/day)
Study: 10333347
Drug: valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 160 mg
Study: 17459221
Drug: Ulinastatin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (300 K units per day) + thymosin alpha1 (Maipuxin, 1.6 mg per day) for 7 days (treatment group 1)
Study: 17459221
Drug: Double dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dosage of Ulinastatin and thymosin alpha1 (treatment group 2)
Study: 15141331
Drug: Oral DFMO
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral DFMO at 100 mg/kg body weight every 6 h for 14 days
Study: 15141331
Drug: Oral DFMO
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral DFMO at 125 mg/kg body weight every 6 h for 14 days
Study: 15141331
Drug: Oral DFMO
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral DFMO at 100 mg/kg
Study: 15141331
Drug: Oral DFMO
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral DFMO at 125 mg/kg
Study: 30417662
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rivaroxaban 2.5 mg twice‐daily and aspirin 100 mg daily
Study: 30417662
Drug: Rivaroxaban 5
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 5 mg twice‐daily alone
Study: 25148458
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (AIs) therapy
Study: 19955739
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of vitamins (adherence >90% to <99%)
Study: 19955739
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of vitamins (adherence >=99%)
Study: 17190130
Drug: Age and
Normalized name: wound drainage and fistula management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age and intravenous antibiotherapy
Study: 17190130
Drug: Internal medicine/infectious
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal medicine/infectious diseases department
Study: 26779855
Drug: Tapering clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering clopidogrel discontinuation during a two‐week period (n = 25)
Study: 25561347
Drug: Endometrial scratching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial scratching (biopsy procedure twice)
Study: 15983147
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg added to lidocaine infiltration
Study: 15983147
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg injected subcutaneously in the contralateral abdominal wall (Control)
Study: 12923398
Drug: Acetylsalicylate-lysin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylate-lysin (500 mg intravenously)
Study: 12923398
Drug: Parecoxib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (20 mg intravenously)
Study: 10540095
Drug: Granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1 mg plus dexamethasone 5 mg
Study: 9103076
Drug: Cell free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell free staphylococcal vaccine
Study: 9103076
Drug: Commercial preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial preparation of staphylococcal antiphagin (Control Group 1)
Study: 9103076
Drug: Traditional methods
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional methods without vaccines (Control Group 2)
Study: 6678385
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of clonidine hydrochloride (Group 1)
Study: 6678385
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of clonidine hydrochloride (Group 2)
Study: 31919579
Drug: Bilastine 10
Normalized name: Bilastine 10 mg orodispersible tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilastine 10 mg/day
Study: 30472992
Drug: Intensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive periodontal treatment (IPT) including whole mouth subgingival scaling, surgical periodontal therapy (if good oral hygiene), and supportive periodontal therapy every 3 months.
Study: 30472992
Drug: Control periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control periodontal treatment (CPT) including supra-gingival scaling and polishing at the same timepoints as in the IPT group.
Study: 30472992
Drug: Control periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control periodontal treatment (CPT)
Study: 22691021
Drug: Forgiveness treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forgiveness treatment (n=41)
Study: 22691021
Drug: Anger-reduction treatment
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anger-reduction treatment (n=39)
Study: 18548293
Drug: Conventional nonsurgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional nonsurgical treatment
Study: 15370078
Drug: L-Arginine (L-Arg
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine (L-Arg 20 g/500 ml)
Study: 11080405
Drug: dimenhydrinate 50
Normalized name: dimenhydrinate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dimenhydrinate 50 mg IV
Study: 9396185
Drug: Meta-analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meta-analysis of treatments
Study: 24704801
Drug: Pre‐emptive methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐emptive methylprednisolone infusion (5 mg/kg) before radiotherapy (Group 1)
Study: 24704801
Drug: Short‐course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short‐course radiotherapy without methylprednisolone infusion (Group 2)
Study: 24704801
Drug: Pre‐emptive methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐emptive methylprednisolone infusion (Group 1)
Study: 15869338
Drug: Empirically supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirically supported treatments (ESTs)
Study: 12592686
Drug: Astragalus injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus injection (20 ml in 250 ml of normal saline, once per day for 21 days, 4 courses)
Study: 10342509
Drug: Terlipressin-glycerin trinitrate
Normalized name: Glycerin trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin-glycerin trinitrate combination (TER-GTN)
Study: 8564726
Drug: Terfenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (120 mg/die for 7 days)
Study: 1720262
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose aprotinin (2 million KIU after induction of anesthesia followed by 500,000 KIU/h infusion throughout the operation)
Study: 31852355
Drug: 6-grass-pollen-allergoid (Allergovit®)
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-grass-pollen-allergoid (Allergovit®) treatment initiated during pollen season (Group-A)
Study: 31852355
Drug: 6-grass-pollen-allergoid (Allergovit®)
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-grass-pollen-allergoid (Allergovit®) treatment initiated outside pollen season (Group-B)
Study: 25495666
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy tablet (SLIT-tablet) MK-7243 (2800 BAU/75 000 SQ-T)
Study: 25331064
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue injection
Study: 22342469
Drug: Oral danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral danazol 600mg
Study: 16222884
Drug: FGF 1
Normalized name: Fibroblast Growth Factor 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF 1 l/min
Study: 16222884
Drug: FGF 2
Normalized name: FGF 2
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF 2 l/min
Study: 16222884
Drug: FGF 4
Normalized name: Fibroblast Growth Factor 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF 4 l/min
Study: 10431937
Drug: Self-monitoring intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-monitoring intervention with additional phone calls and daily mailings during the holiday season
Study: 10431937
Drug: Standard weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weekly cognitive-behavioral treatment for obesity (comparison group)
Study: 7589022
Drug: Dipyrone 2
Normalized name: dipyrone 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 2 g i.m.
Study: 7589022
Drug: Dipyrone 2
Normalized name: dipyrone 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 2 g i.v.
Study: 7589022
Drug: Dipyrone 1
Normalized name: dipyrone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 1 g i.m.
Study: 7589022
Drug: Dipyrone 1
Normalized name: dipyrone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 1 g i.v.
Study: 7589022
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 75 mg i.m.
Study: 7589022
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 75 mg i.v.
Study: 2405777
Drug: Radiation.MCNU (MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation.MCNU (MR group) with 50-60 Gy irradiation and 2 mg/kg MCNU intravenously on the initial day and 6 weeks later.
Study: 2405777
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of MCNU and interferon-beta.
Study: 11777176
Drug: Intravenous prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prostaglandin E1 (PGE1)
Study: 31492661
Drug: Increased abdominal
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased abdominal subcutaneous adipose tissue (ScAT) inflammatory gene expression
Study: 26718394
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) designed to reduce drinking to cope (DTC) and anxiety symptoms
Study: 19357642
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg per day)
Study: 19357642
Drug: Inhaled beclometasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclometasone dipropionate (200 microg per day)
Study: 20335624
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10-20 mg/d for 4 to 15 months)
Study: 16270384
Drug: Purple sweet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple sweet potato leaves (PSPL) diet (daily consumption of 200 g PSPL)
Study: 11875328
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (25-microg and 50-microg E(2) patch)
Study: 11875328
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (100-microg E(2) patch)
Study: 11875328
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50-microg E(2) patch combined with P (300 mg/day) or MPA (5 mg/day))
Study: 11875328
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E(2)) alone
Study: 11875328
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E(2)) plus progestogen
Study: 29486338
Drug: Palmitoylethanolamide (PEA)
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoylethanolamide (PEA) 600 mg twice daily
Study: 25195352
Drug: P. oleracea
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. oleracea seeds (500 mg) taken two times a day for one month
Study: 25195352
Drug: Placebo (lactose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose) capsules taken two times a day for one month
Study: 20510551
Drug: oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral methadone
Study: 16438017
Drug: Oral 10
Normalized name: Syringe Oral 10cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 10 mg diazepam in the evening before surgery and 1.5 mg midazolam at least 15 min before surgery
Study: 12592230
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg per day for 6 weeks)
Study: 10100957
Drug: Daily plasmapheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily plasmapheresis
Study: 10100957
Drug: Alternately daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternately daily plasmapheresis
Study: 26791869
Drug: ch14.18-UTC (17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ch14.18-UTC (17.5 mg/m²/day)
Study: 26791869
Drug: ch14.18-NCI (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ch14.18-NCI (25 mg/m²/day)
Study: 20564152
Drug: Historic control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historic control group (HCG) receiving the same chemotherapy regimen and irradiation at doses of 40 Gy and 30 Gy, respectively.
Study: 16499954
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with 2 mg 17beta‐estradiol plus 1 mg norethisterone acetate (n=30)
Study: 16499954
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg raloxifene (n=24)
Study: 1815302
Drug: Pyridostigmine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (120 mg orally)
Study: 7476342
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets orally)
Study: 30615896
Drug: Immediate prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate prescription of glasses (1.00 D less than full cycloplegic hyperopia)
Study: 28114954
Drug: Endoscopic sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic sinus surgery in addition to medication
Study: 12645641
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy only
Study: 15476905
Drug: Olopatadine hydrochloride
Normalized name: Olopatadine Hydrochloride
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine hydrochloride ophthalmic solution 0.2%
Study: 11778075
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 microg/kg subcutaneously until Day 13 after PBPCT)
Study: 31658265
Drug: Sterile males
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile males produced from combining the sterile insect technique using radiation with the insect incompatible technique through Wolbachia‐induced incompatibility (SIT/IIT); approximately 100-200 sterile males released weekly in each household for 6 months.
Study: 29397189
Drug: 342 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 342 μg IBI‐10090 dexamethasone drug delivery suspension
Study: 29397189
Drug: 517 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 517 μg IBI‐10090 dexamethasone drug delivery suspension
Study: 24918735
Drug: Cultured epithelial
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultured epithelial autografts (JACE) combined with autograft and artificial dermis preparation
Study: 31687205
Drug: Olmesartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (20 mg/day)
Study: 19513973
Drug: Acemetacin (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin (180 mg/day)
Study: 17489767
Drug: Fibrinolytics (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytics (administered within six hours of first chest symptoms)
Study: 17489767
Drug: Anticoagulants (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (administered after optimal time)